A Double-Blind, Randomized, Placebo and Active Controlled Study to Evaluate the Efficacy and Safety of Once Daily, Extended Release Levetiracetam as Add-on Therapy in Patients with Refractory Partial Onset Epilepsy.

Refractory Partial Onset Epilepsy

Percent change from baseline* in FOS frequency per week over the 12 week double-blind period.

Change from baseline* in absolute FOS over the 12 week double-blind period., Proportion of subjects with at least 50% reduction from baseline* in total seizure frequency per week over the 12 week double-blind period., Proportion of subjects with at least 50% reduction from baseline* in total seizures over the 12 week double-blind period., Number of days free of FOS over the treatment period of 12 weeks., Response in Weekly FOS Frequency (Categorized Into 6 Categories According to Reduction) Over the Treatment Period of 12 Weeks)., Change in the Quality of Life in Epilepsy (QoLIE-31) scale score (patients ≥18 years) and QoLIE- AD-48 (age <18 years) over the study period., Improving medication compliance and patient satisfaction with the treatment over the study period.

No related papers found yet.

Bulgaria, Czechia, Germany, Greece, Hungary, Italy, Poland, Romania, Spain